Megan A Waldrop

Contact Information

Call us at: (614) 722-2203

Fax us at: (614) 355-5247

PediatricsNeurology700 Children’s DrColumbus, OH 43205 (map)

Learn more about Megan A. Waldrop

Biography

Megan Waldrop, MD, is a pediatric neurologist at Nationwide Children’s Hospital and an assistant professor of Pediatrics and Neurology at The Ohio State University College of Medicine. She completed her Pediatrics and Child Neurology training at the Children’s Hospital of Orange County/University of California, Irvine School of Medicine. She completed a Neuromuscular Medicine fellowship at Ohio State University/Nationwide Children’s Hospital and a Neuromuscular Genetics Therapeutics fellowship at Nationwide Children’s Hospital. She is board certified in Neuromuscular Medicine and Neurology with special qualifications in Child Neurology. Her clinical and research interests include muscular dystrophy, congenital myopathy and spinal muscular atrophy, with a particular interest in diagnosing rare neuromuscular diseases.

Academic and Clinical Areas

Neurology

Physician Team

Neuromuscular Disorders

Physician Team

Neurology Residency

Faculty

Primary Department

Pediatrics

Primary Section

Neurology

Research

Publications

                  Flanigan KM, Vetter TA, Simmons TR, Iammarino M, Frair EC, Rinaldi F, Chicoine LG, Harris J, Cheatham JP, Cheatham SL, Boe B, Waldrop MA, Zygmunt DA, Packer D, Martin PT. A first-in-human phase I/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2. Mol Ther Methods Clin Dev. 2022 Dec 8; 27: 47-60.

                


                  Waldrop MA, Moore SA, Mathews KD, Darbro BW, Medne L, Finkel R, Connolly AM, Crawford TO, Drachman D, Wein N, Habib AA, Krzesniak-Swinarska MA, Zaidman CM, Collins JJ, Jokela M, Udd B, Day JW, Ortiz-Guerrero G, Statland J, Butterfield RJ, Dunn DM, Weiss RB, Flanigan KM. Intron Mutations and Early Transcription Termination in Duchenne and Becker muscular dystrophy. Hum Mutat. 2022 Feb 14;  

                


                  Zambon AA, Waldrop MA, Alles R, Weiss RB, Conroy S, Moore-Clingenpeel M, Previtali S, Flanigan KM, Italian DMD Network and the United Dystrophinopathy Project (UDP).. Phenotypic Spectrum of Dystrophinopathy Due to Duchenne Muscular Dystrophy Exon 2 Duplications. Neurology. 2021 Dec 22;  

                


                  Wein N, Dunn DM, Waldrop MA, Gushchina LV, Frair EC, Weiss RB, Flanigan KM. Absence of Significant Off-Target Splicing Variation with a U7snRNA Vector Targeting DMD Exon 2 Duplications. Hum Gene Ther. 2021 Nov; 32: 1346-1359.

                


                  Alfano LN, Iammarino MA, Reash NF, Powers BR, Shannon K, Connolly AM, Waldrop MA, Noritz GH, Shell R, Tsao CY, Flanigan KM, Mendell JR, Lowes LP. Validity and Reliability of the Neuromuscular Gross Motor Outcome. Pediatr Neurol. 2021 Sep; 122: 21-26.

                


                  Gushchina LV, Frair EC, Rohan N, Bradley AJ, Simmons TR, Chavan HD, Chou HJ, Eggers M, Waldrop MA, Wein N, Flanigan KM. Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce DMD Exon 2 Skipping. Hum Gene Ther. 2021 Sep; 32: 882-894.

                


                  Lee BH, Waldrop MA, Connolly AM, Ciafaloni E. Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy. Muscle Nerve. 2021 Aug; 64: 153-155.

                


                  Nicolau S, Waldrop MA, Connolly AM, Mendell JR. Spinal Muscular Atrophy. Semin Pediatr Neurol. 2021 Apr; 37: 100878.

                


                  Abreu NJ, Waldrop MA. Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy. Pediatr Pulmonol. 2021 Apr; 56: 710-720.

                


                  Nizon M, Laugel V, Flanigan KM, Pastore M, Waldrop MA, Rosenfeld JA, Marom R, Xiao R, Gerard A, Pichon O, Le Caignec C, Gérard M, Dieterich K, Truitt Cho M, McWalter K, Hiatt S, Thompson ML, Bézieau S, Wadley A, Wierenga KJ, Egly JM, Isidor B. Variants in MED12L, encoding a subunit of the mediator kinase module, are responsible for intellectual disability associated with transcriptional defect. Genet Med. 2019 Dec; 21: 2713-2722.

                


                  Waldrop MA, Flanigan KM. Update in Duchenne and Becker muscular dystrophy. Curr Opin Neurol. 2019 Oct; 32: 722-727.

                


                  Nizon M, Laugel V, Flanigan KM, Pastore M, Waldrop MA, Rosenfeld JA, Marom R, Xiao R, Gerard A, Pichon O, Le Caignec C, Gérard M, Dieterich K, Truitt Cho M, McWalter K, Hiatt S, Thompson ML, Bézieau S, Wadley A, Wierenga KJ, Egly JM, Isidor B. Correction: Variants in MED12L, encoding a subunit of the Mediator kinase module, are responsible for intellectual disability associated with transcriptional defect. Genet Med. 2019 Jul 3;  

                


                  Waldrop MA, Kolb SJ. Current Treatment Options in Neurology-SMA Therapeutics. Curr Treat Options Neurol. 2019 Apr 29; 21: 25.

                


                  Waldrop MA, Pastore M, Schrader R, Sites E, Bartholomew D, Tsao CY, Flanigan KM. Diagnostic Utility of Whole Exome Sequencing in the Neuromuscular Clinic. Neuropediatrics. 2019 Apr; 50: 96-102.

View More Publications

Education

Date of Appointment at Nationwide Children’s Hospital: 04/01/2018

Board Certifications

Child Neurology Neurology Neuromuscular Medicine

Fellowship

Nationwide Children’s Hospital

Date Completed: 03/31/2018

Fellowship

Ohio State University Wexner Medical Center

Date Completed: 06/30/2017

Residency

University of California Irvine Medical Center

Date Completed: 06/30/2016

Residency

University of California Irvine Medical Center

Date Completed: 06/30/2013

Medical School

Albany Medical College

Date Completed: 05/26/2011

Contact Information

Pediatrics

Call us at: (614) 722-2203

Fax us at: (614) 355-5247

                    Neurology700 Children's DrColumbus, OH 43205 (map)

Contact Information

Call us at: (614) 722-2203

Fax us at: (614) 355-5247

PediatricsNeurology700 Children’s DrColumbus, OH 43205 (map)

Learn more about Megan A. Waldrop

Biography

Megan Waldrop, MD, is a pediatric neurologist at Nationwide Children’s Hospital and an assistant professor of Pediatrics and Neurology at The Ohio State University College of Medicine. She completed her Pediatrics and Child Neurology training at the Children’s Hospital of Orange County/University of California, Irvine School of Medicine. She completed a Neuromuscular Medicine fellowship at Ohio State University/Nationwide Children’s Hospital and a Neuromuscular Genetics Therapeutics fellowship at Nationwide Children’s Hospital. She is board certified in Neuromuscular Medicine and Neurology with special qualifications in Child Neurology. Her clinical and research interests include muscular dystrophy, congenital myopathy and spinal muscular atrophy, with a particular interest in diagnosing rare neuromuscular diseases.

Academic and Clinical Areas

Neurology

Physician Team

Neuromuscular Disorders

Physician Team

Neurology Residency

Faculty

Primary Department

Pediatrics

Primary Section

Neurology

Research

Publications

                  Flanigan KM, Vetter TA, Simmons TR, Iammarino M, Frair EC, Rinaldi F, Chicoine LG, Harris J, Cheatham JP, Cheatham SL, Boe B, Waldrop MA, Zygmunt DA, Packer D, Martin PT. A first-in-human phase I/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2. Mol Ther Methods Clin Dev. 2022 Dec 8; 27: 47-60.

                


                  Waldrop MA, Moore SA, Mathews KD, Darbro BW, Medne L, Finkel R, Connolly AM, Crawford TO, Drachman D, Wein N, Habib AA, Krzesniak-Swinarska MA, Zaidman CM, Collins JJ, Jokela M, Udd B, Day JW, Ortiz-Guerrero G, Statland J, Butterfield RJ, Dunn DM, Weiss RB, Flanigan KM. Intron Mutations and Early Transcription Termination in Duchenne and Becker muscular dystrophy. Hum Mutat. 2022 Feb 14;  

                


                  Zambon AA, Waldrop MA, Alles R, Weiss RB, Conroy S, Moore-Clingenpeel M, Previtali S, Flanigan KM, Italian DMD Network and the United Dystrophinopathy Project (UDP).. Phenotypic Spectrum of Dystrophinopathy Due to Duchenne Muscular Dystrophy Exon 2 Duplications. Neurology. 2021 Dec 22;  

                


                  Wein N, Dunn DM, Waldrop MA, Gushchina LV, Frair EC, Weiss RB, Flanigan KM. Absence of Significant Off-Target Splicing Variation with a U7snRNA Vector Targeting DMD Exon 2 Duplications. Hum Gene Ther. 2021 Nov; 32: 1346-1359.

                


                  Alfano LN, Iammarino MA, Reash NF, Powers BR, Shannon K, Connolly AM, Waldrop MA, Noritz GH, Shell R, Tsao CY, Flanigan KM, Mendell JR, Lowes LP. Validity and Reliability of the Neuromuscular Gross Motor Outcome. Pediatr Neurol. 2021 Sep; 122: 21-26.

                


                  Gushchina LV, Frair EC, Rohan N, Bradley AJ, Simmons TR, Chavan HD, Chou HJ, Eggers M, Waldrop MA, Wein N, Flanigan KM. Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce DMD Exon 2 Skipping. Hum Gene Ther. 2021 Sep; 32: 882-894.

                


                  Lee BH, Waldrop MA, Connolly AM, Ciafaloni E. Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy. Muscle Nerve. 2021 Aug; 64: 153-155.

                


                  Nicolau S, Waldrop MA, Connolly AM, Mendell JR. Spinal Muscular Atrophy. Semin Pediatr Neurol. 2021 Apr; 37: 100878.

                


                  Abreu NJ, Waldrop MA. Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy. Pediatr Pulmonol. 2021 Apr; 56: 710-720.

                


                  Nizon M, Laugel V, Flanigan KM, Pastore M, Waldrop MA, Rosenfeld JA, Marom R, Xiao R, Gerard A, Pichon O, Le Caignec C, Gérard M, Dieterich K, Truitt Cho M, McWalter K, Hiatt S, Thompson ML, Bézieau S, Wadley A, Wierenga KJ, Egly JM, Isidor B. Variants in MED12L, encoding a subunit of the mediator kinase module, are responsible for intellectual disability associated with transcriptional defect. Genet Med. 2019 Dec; 21: 2713-2722.

                


                  Waldrop MA, Flanigan KM. Update in Duchenne and Becker muscular dystrophy. Curr Opin Neurol. 2019 Oct; 32: 722-727.

                


                  Nizon M, Laugel V, Flanigan KM, Pastore M, Waldrop MA, Rosenfeld JA, Marom R, Xiao R, Gerard A, Pichon O, Le Caignec C, Gérard M, Dieterich K, Truitt Cho M, McWalter K, Hiatt S, Thompson ML, Bézieau S, Wadley A, Wierenga KJ, Egly JM, Isidor B. Correction: Variants in MED12L, encoding a subunit of the Mediator kinase module, are responsible for intellectual disability associated with transcriptional defect. Genet Med. 2019 Jul 3;  

                


                  Waldrop MA, Kolb SJ. Current Treatment Options in Neurology-SMA Therapeutics. Curr Treat Options Neurol. 2019 Apr 29; 21: 25.

                


                  Waldrop MA, Pastore M, Schrader R, Sites E, Bartholomew D, Tsao CY, Flanigan KM. Diagnostic Utility of Whole Exome Sequencing in the Neuromuscular Clinic. Neuropediatrics. 2019 Apr; 50: 96-102.

View More Publications

Education

Date of Appointment at Nationwide Children’s Hospital: 04/01/2018

Board Certifications

Child Neurology Neurology Neuromuscular Medicine

Fellowship

Nationwide Children’s Hospital

Date Completed: 03/31/2018

Fellowship

Ohio State University Wexner Medical Center

Date Completed: 06/30/2017

Residency

University of California Irvine Medical Center

Date Completed: 06/30/2016

Residency

University of California Irvine Medical Center

Date Completed: 06/30/2013

Medical School

Albany Medical College

Date Completed: 05/26/2011

Contact Information

Pediatrics

Call us at: (614) 722-2203

Fax us at: (614) 355-5247

                    Neurology700 Children's DrColumbus, OH 43205 (map)

Contact Information

Call us at: (614) 722-2203

Fax us at: (614) 355-5247

PediatricsNeurology700 Children’s DrColumbus, OH 43205 (map)

Learn more about Megan A. Waldrop

Contact Information

• Call us at:
• (614) 722-2203
• Fax us at:
• (614) 355-5247
• PediatricsNeurology700 Children’s DrColumbus, OH 43205 (map)

Learn more about Megan A. Waldrop

Biography

Megan Waldrop, MD, is a pediatric neurologist at Nationwide Children’s Hospital and an assistant professor of Pediatrics and Neurology at The Ohio State University College of Medicine. She completed her Pediatrics and Child Neurology training at the Children’s Hospital of Orange County/University of California, Irvine School of Medicine. She completed a Neuromuscular Medicine fellowship at Ohio State University/Nationwide Children’s Hospital and a Neuromuscular Genetics Therapeutics fellowship at Nationwide Children’s Hospital. She is board certified in Neuromuscular Medicine and Neurology with special qualifications in Child Neurology. Her clinical and research interests include muscular dystrophy, congenital myopathy and spinal muscular atrophy, with a particular interest in diagnosing rare neuromuscular diseases.

Biography

Megan Waldrop, MD, is a pediatric neurologist at Nationwide Children’s Hospital and an assistant professor of Pediatrics and Neurology at The Ohio State University College of Medicine. She completed her Pediatrics and Child Neurology training at the Children’s Hospital of Orange County/University of California, Irvine School of Medicine. She completed a Neuromuscular Medicine fellowship at Ohio State University/Nationwide Children’s Hospital and a Neuromuscular Genetics Therapeutics fellowship at Nationwide Children’s Hospital. She is board certified in Neuromuscular Medicine and Neurology with special qualifications in Child Neurology. Her clinical and research interests include muscular dystrophy, congenital myopathy and spinal muscular atrophy, with a particular interest in diagnosing rare neuromuscular diseases.

Biography

Megan Waldrop, MD, is a pediatric neurologist at Nationwide Children’s Hospital and an assistant professor of Pediatrics and Neurology at The Ohio State University College of Medicine. She completed her Pediatrics and Child Neurology training at the Children’s Hospital of Orange County/University of California, Irvine School of Medicine. She completed a Neuromuscular Medicine fellowship at Ohio State University/Nationwide Children’s Hospital and a Neuromuscular Genetics Therapeutics fellowship at Nationwide Children’s Hospital. She is board certified in Neuromuscular Medicine and Neurology with special qualifications in Child Neurology. Her clinical and research interests include muscular dystrophy, congenital myopathy and spinal muscular atrophy, with a particular interest in diagnosing rare neuromuscular diseases.

Megan Waldrop, MD, is a pediatric neurologist at Nationwide Children’s Hospital and an assistant professor of Pediatrics and Neurology at The Ohio State University College of Medicine. She completed her Pediatrics and Child Neurology training at the Children’s Hospital of Orange County/University of California, Irvine School of Medicine. She completed a Neuromuscular Medicine fellowship at Ohio State University/Nationwide Children’s Hospital and a Neuromuscular Genetics Therapeutics fellowship at Nationwide Children’s Hospital. She is board certified in Neuromuscular Medicine and Neurology with special qualifications in Child Neurology. Her clinical and research interests include muscular dystrophy, congenital myopathy and spinal muscular atrophy, with a particular interest in diagnosing rare neuromuscular diseases.

Megan Waldrop, MD, is a pediatric neurologist at Nationwide Children’s Hospital and an assistant professor of Pediatrics and Neurology at The Ohio State University College of Medicine. She completed her Pediatrics and Child Neurology training at the Children’s Hospital of Orange County/University of California, Irvine School of Medicine. She completed a Neuromuscular Medicine fellowship at Ohio State University/Nationwide Children’s Hospital and a Neuromuscular Genetics Therapeutics fellowship at Nationwide Children’s Hospital.

She is board certified in Neuromuscular Medicine and Neurology with special qualifications in Child Neurology. Her clinical and research interests include muscular dystrophy, congenital myopathy and spinal muscular atrophy, with a particular interest in diagnosing rare neuromuscular diseases.

Academic and Clinical Areas

Neurology

Physician Team

Neuromuscular Disorders

Physician Team

Neurology Residency

Faculty

Primary Department

Pediatrics

Primary Section

Neurology

Academic and Clinical Areas

Neurology

Physician Team

Neuromuscular Disorders

Physician Team

Neurology Residency

Faculty

Primary Department

Pediatrics

Primary Section

Neurology

Academic and Clinical Areas

Neurology

Physician Team

Neuromuscular Disorders

Physician Team

Neurology Residency

Faculty

Primary Department

Pediatrics

Primary Section

Neurology

Neurology

Physician Team

Neuromuscular Disorders

Physician Team

Neurology Residency

Faculty

Primary Department

Pediatrics

Primary Section

Neurology

• Neurology
• Physician Team
• Neuromuscular Disorders
• Physician Team
• Neurology Residency
• Faculty
• Primary Department
• Pediatrics
• Primary Section
• Neurology

Research

Publications

                  Flanigan KM, Vetter TA, Simmons TR, Iammarino M, Frair EC, Rinaldi F, Chicoine LG, Harris J, Cheatham JP, Cheatham SL, Boe B, Waldrop MA, Zygmunt DA, Packer D, Martin PT. A first-in-human phase I/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2. Mol Ther Methods Clin Dev. 2022 Dec 8; 27: 47-60.

                


                  Waldrop MA, Moore SA, Mathews KD, Darbro BW, Medne L, Finkel R, Connolly AM, Crawford TO, Drachman D, Wein N, Habib AA, Krzesniak-Swinarska MA, Zaidman CM, Collins JJ, Jokela M, Udd B, Day JW, Ortiz-Guerrero G, Statland J, Butterfield RJ, Dunn DM, Weiss RB, Flanigan KM. Intron Mutations and Early Transcription Termination in Duchenne and Becker muscular dystrophy. Hum Mutat. 2022 Feb 14;  

                


                  Zambon AA, Waldrop MA, Alles R, Weiss RB, Conroy S, Moore-Clingenpeel M, Previtali S, Flanigan KM, Italian DMD Network and the United Dystrophinopathy Project (UDP).. Phenotypic Spectrum of Dystrophinopathy Due to Duchenne Muscular Dystrophy Exon 2 Duplications. Neurology. 2021 Dec 22;  

                


                  Wein N, Dunn DM, Waldrop MA, Gushchina LV, Frair EC, Weiss RB, Flanigan KM. Absence of Significant Off-Target Splicing Variation with a U7snRNA Vector Targeting DMD Exon 2 Duplications. Hum Gene Ther. 2021 Nov; 32: 1346-1359.

                


                  Alfano LN, Iammarino MA, Reash NF, Powers BR, Shannon K, Connolly AM, Waldrop MA, Noritz GH, Shell R, Tsao CY, Flanigan KM, Mendell JR, Lowes LP. Validity and Reliability of the Neuromuscular Gross Motor Outcome. Pediatr Neurol. 2021 Sep; 122: 21-26.

                


                  Gushchina LV, Frair EC, Rohan N, Bradley AJ, Simmons TR, Chavan HD, Chou HJ, Eggers M, Waldrop MA, Wein N, Flanigan KM. Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce DMD Exon 2 Skipping. Hum Gene Ther. 2021 Sep; 32: 882-894.

                


                  Lee BH, Waldrop MA, Connolly AM, Ciafaloni E. Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy. Muscle Nerve. 2021 Aug; 64: 153-155.

                


                  Nicolau S, Waldrop MA, Connolly AM, Mendell JR. Spinal Muscular Atrophy. Semin Pediatr Neurol. 2021 Apr; 37: 100878.

                


                  Abreu NJ, Waldrop MA. Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy. Pediatr Pulmonol. 2021 Apr; 56: 710-720.

                


                  Nizon M, Laugel V, Flanigan KM, Pastore M, Waldrop MA, Rosenfeld JA, Marom R, Xiao R, Gerard A, Pichon O, Le Caignec C, Gérard M, Dieterich K, Truitt Cho M, McWalter K, Hiatt S, Thompson ML, Bézieau S, Wadley A, Wierenga KJ, Egly JM, Isidor B. Variants in MED12L, encoding a subunit of the mediator kinase module, are responsible for intellectual disability associated with transcriptional defect. Genet Med. 2019 Dec; 21: 2713-2722.

                


                  Waldrop MA, Flanigan KM. Update in Duchenne and Becker muscular dystrophy. Curr Opin Neurol. 2019 Oct; 32: 722-727.

                


                  Nizon M, Laugel V, Flanigan KM, Pastore M, Waldrop MA, Rosenfeld JA, Marom R, Xiao R, Gerard A, Pichon O, Le Caignec C, Gérard M, Dieterich K, Truitt Cho M, McWalter K, Hiatt S, Thompson ML, Bézieau S, Wadley A, Wierenga KJ, Egly JM, Isidor B. Correction: Variants in MED12L, encoding a subunit of the Mediator kinase module, are responsible for intellectual disability associated with transcriptional defect. Genet Med. 2019 Jul 3;  

                


                  Waldrop MA, Kolb SJ. Current Treatment Options in Neurology-SMA Therapeutics. Curr Treat Options Neurol. 2019 Apr 29; 21: 25.

                


                  Waldrop MA, Pastore M, Schrader R, Sites E, Bartholomew D, Tsao CY, Flanigan KM. Diagnostic Utility of Whole Exome Sequencing in the Neuromuscular Clinic. Neuropediatrics. 2019 Apr; 50: 96-102.

View More Publications

Research

Publications

                  Flanigan KM, Vetter TA, Simmons TR, Iammarino M, Frair EC, Rinaldi F, Chicoine LG, Harris J, Cheatham JP, Cheatham SL, Boe B, Waldrop MA, Zygmunt DA, Packer D, Martin PT. A first-in-human phase I/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2. Mol Ther Methods Clin Dev. 2022 Dec 8; 27: 47-60.

                


                  Waldrop MA, Moore SA, Mathews KD, Darbro BW, Medne L, Finkel R, Connolly AM, Crawford TO, Drachman D, Wein N, Habib AA, Krzesniak-Swinarska MA, Zaidman CM, Collins JJ, Jokela M, Udd B, Day JW, Ortiz-Guerrero G, Statland J, Butterfield RJ, Dunn DM, Weiss RB, Flanigan KM. Intron Mutations and Early Transcription Termination in Duchenne and Becker muscular dystrophy. Hum Mutat. 2022 Feb 14;  

                


                  Zambon AA, Waldrop MA, Alles R, Weiss RB, Conroy S, Moore-Clingenpeel M, Previtali S, Flanigan KM, Italian DMD Network and the United Dystrophinopathy Project (UDP).. Phenotypic Spectrum of Dystrophinopathy Due to Duchenne Muscular Dystrophy Exon 2 Duplications. Neurology. 2021 Dec 22;  

                


                  Wein N, Dunn DM, Waldrop MA, Gushchina LV, Frair EC, Weiss RB, Flanigan KM. Absence of Significant Off-Target Splicing Variation with a U7snRNA Vector Targeting DMD Exon 2 Duplications. Hum Gene Ther. 2021 Nov; 32: 1346-1359.

                


                  Alfano LN, Iammarino MA, Reash NF, Powers BR, Shannon K, Connolly AM, Waldrop MA, Noritz GH, Shell R, Tsao CY, Flanigan KM, Mendell JR, Lowes LP. Validity and Reliability of the Neuromuscular Gross Motor Outcome. Pediatr Neurol. 2021 Sep; 122: 21-26.

                


                  Gushchina LV, Frair EC, Rohan N, Bradley AJ, Simmons TR, Chavan HD, Chou HJ, Eggers M, Waldrop MA, Wein N, Flanigan KM. Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce DMD Exon 2 Skipping. Hum Gene Ther. 2021 Sep; 32: 882-894.

                


                  Lee BH, Waldrop MA, Connolly AM, Ciafaloni E. Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy. Muscle Nerve. 2021 Aug; 64: 153-155.

                


                  Nicolau S, Waldrop MA, Connolly AM, Mendell JR. Spinal Muscular Atrophy. Semin Pediatr Neurol. 2021 Apr; 37: 100878.

                


                  Abreu NJ, Waldrop MA. Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy. Pediatr Pulmonol. 2021 Apr; 56: 710-720.

                


                  Nizon M, Laugel V, Flanigan KM, Pastore M, Waldrop MA, Rosenfeld JA, Marom R, Xiao R, Gerard A, Pichon O, Le Caignec C, Gérard M, Dieterich K, Truitt Cho M, McWalter K, Hiatt S, Thompson ML, Bézieau S, Wadley A, Wierenga KJ, Egly JM, Isidor B. Variants in MED12L, encoding a subunit of the mediator kinase module, are responsible for intellectual disability associated with transcriptional defect. Genet Med. 2019 Dec; 21: 2713-2722.

                


                  Waldrop MA, Flanigan KM. Update in Duchenne and Becker muscular dystrophy. Curr Opin Neurol. 2019 Oct; 32: 722-727.

                


                  Nizon M, Laugel V, Flanigan KM, Pastore M, Waldrop MA, Rosenfeld JA, Marom R, Xiao R, Gerard A, Pichon O, Le Caignec C, Gérard M, Dieterich K, Truitt Cho M, McWalter K, Hiatt S, Thompson ML, Bézieau S, Wadley A, Wierenga KJ, Egly JM, Isidor B. Correction: Variants in MED12L, encoding a subunit of the Mediator kinase module, are responsible for intellectual disability associated with transcriptional defect. Genet Med. 2019 Jul 3;  

                


                  Waldrop MA, Kolb SJ. Current Treatment Options in Neurology-SMA Therapeutics. Curr Treat Options Neurol. 2019 Apr 29; 21: 25.

                


                  Waldrop MA, Pastore M, Schrader R, Sites E, Bartholomew D, Tsao CY, Flanigan KM. Diagnostic Utility of Whole Exome Sequencing in the Neuromuscular Clinic. Neuropediatrics. 2019 Apr; 50: 96-102.

View More Publications

Research

Publications

                  Flanigan KM, Vetter TA, Simmons TR, Iammarino M, Frair EC, Rinaldi F, Chicoine LG, Harris J, Cheatham JP, Cheatham SL, Boe B, Waldrop MA, Zygmunt DA, Packer D, Martin PT. A first-in-human phase I/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2. Mol Ther Methods Clin Dev. 2022 Dec 8; 27: 47-60.

                


                  Waldrop MA, Moore SA, Mathews KD, Darbro BW, Medne L, Finkel R, Connolly AM, Crawford TO, Drachman D, Wein N, Habib AA, Krzesniak-Swinarska MA, Zaidman CM, Collins JJ, Jokela M, Udd B, Day JW, Ortiz-Guerrero G, Statland J, Butterfield RJ, Dunn DM, Weiss RB, Flanigan KM. Intron Mutations and Early Transcription Termination in Duchenne and Becker muscular dystrophy. Hum Mutat. 2022 Feb 14;  

                


                  Zambon AA, Waldrop MA, Alles R, Weiss RB, Conroy S, Moore-Clingenpeel M, Previtali S, Flanigan KM, Italian DMD Network and the United Dystrophinopathy Project (UDP).. Phenotypic Spectrum of Dystrophinopathy Due to Duchenne Muscular Dystrophy Exon 2 Duplications. Neurology. 2021 Dec 22;  

                


                  Wein N, Dunn DM, Waldrop MA, Gushchina LV, Frair EC, Weiss RB, Flanigan KM. Absence of Significant Off-Target Splicing Variation with a U7snRNA Vector Targeting DMD Exon 2 Duplications. Hum Gene Ther. 2021 Nov; 32: 1346-1359.

                


                  Alfano LN, Iammarino MA, Reash NF, Powers BR, Shannon K, Connolly AM, Waldrop MA, Noritz GH, Shell R, Tsao CY, Flanigan KM, Mendell JR, Lowes LP. Validity and Reliability of the Neuromuscular Gross Motor Outcome. Pediatr Neurol. 2021 Sep; 122: 21-26.

                


                  Gushchina LV, Frair EC, Rohan N, Bradley AJ, Simmons TR, Chavan HD, Chou HJ, Eggers M, Waldrop MA, Wein N, Flanigan KM. Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce DMD Exon 2 Skipping. Hum Gene Ther. 2021 Sep; 32: 882-894.

                


                  Lee BH, Waldrop MA, Connolly AM, Ciafaloni E. Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy. Muscle Nerve. 2021 Aug; 64: 153-155.

                


                  Nicolau S, Waldrop MA, Connolly AM, Mendell JR. Spinal Muscular Atrophy. Semin Pediatr Neurol. 2021 Apr; 37: 100878.

                


                  Abreu NJ, Waldrop MA. Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy. Pediatr Pulmonol. 2021 Apr; 56: 710-720.

                


                  Nizon M, Laugel V, Flanigan KM, Pastore M, Waldrop MA, Rosenfeld JA, Marom R, Xiao R, Gerard A, Pichon O, Le Caignec C, Gérard M, Dieterich K, Truitt Cho M, McWalter K, Hiatt S, Thompson ML, Bézieau S, Wadley A, Wierenga KJ, Egly JM, Isidor B. Variants in MED12L, encoding a subunit of the mediator kinase module, are responsible for intellectual disability associated with transcriptional defect. Genet Med. 2019 Dec; 21: 2713-2722.

                


                  Waldrop MA, Flanigan KM. Update in Duchenne and Becker muscular dystrophy. Curr Opin Neurol. 2019 Oct; 32: 722-727.

                


                  Nizon M, Laugel V, Flanigan KM, Pastore M, Waldrop MA, Rosenfeld JA, Marom R, Xiao R, Gerard A, Pichon O, Le Caignec C, Gérard M, Dieterich K, Truitt Cho M, McWalter K, Hiatt S, Thompson ML, Bézieau S, Wadley A, Wierenga KJ, Egly JM, Isidor B. Correction: Variants in MED12L, encoding a subunit of the Mediator kinase module, are responsible for intellectual disability associated with transcriptional defect. Genet Med. 2019 Jul 3;  

                


                  Waldrop MA, Kolb SJ. Current Treatment Options in Neurology-SMA Therapeutics. Curr Treat Options Neurol. 2019 Apr 29; 21: 25.

                


                  Waldrop MA, Pastore M, Schrader R, Sites E, Bartholomew D, Tsao CY, Flanigan KM. Diagnostic Utility of Whole Exome Sequencing in the Neuromuscular Clinic. Neuropediatrics. 2019 Apr; 50: 96-102.

View More Publications

Publications

                  Flanigan KM, Vetter TA, Simmons TR, Iammarino M, Frair EC, Rinaldi F, Chicoine LG, Harris J, Cheatham JP, Cheatham SL, Boe B, Waldrop MA, Zygmunt DA, Packer D, Martin PT. A first-in-human phase I/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2. Mol Ther Methods Clin Dev. 2022 Dec 8; 27: 47-60.

                


                  Waldrop MA, Moore SA, Mathews KD, Darbro BW, Medne L, Finkel R, Connolly AM, Crawford TO, Drachman D, Wein N, Habib AA, Krzesniak-Swinarska MA, Zaidman CM, Collins JJ, Jokela M, Udd B, Day JW, Ortiz-Guerrero G, Statland J, Butterfield RJ, Dunn DM, Weiss RB, Flanigan KM. Intron Mutations and Early Transcription Termination in Duchenne and Becker muscular dystrophy. Hum Mutat. 2022 Feb 14;  

                


                  Zambon AA, Waldrop MA, Alles R, Weiss RB, Conroy S, Moore-Clingenpeel M, Previtali S, Flanigan KM, Italian DMD Network and the United Dystrophinopathy Project (UDP).. Phenotypic Spectrum of Dystrophinopathy Due to Duchenne Muscular Dystrophy Exon 2 Duplications. Neurology. 2021 Dec 22;  

                


                  Wein N, Dunn DM, Waldrop MA, Gushchina LV, Frair EC, Weiss RB, Flanigan KM. Absence of Significant Off-Target Splicing Variation with a U7snRNA Vector Targeting DMD Exon 2 Duplications. Hum Gene Ther. 2021 Nov; 32: 1346-1359.

                


                  Alfano LN, Iammarino MA, Reash NF, Powers BR, Shannon K, Connolly AM, Waldrop MA, Noritz GH, Shell R, Tsao CY, Flanigan KM, Mendell JR, Lowes LP. Validity and Reliability of the Neuromuscular Gross Motor Outcome. Pediatr Neurol. 2021 Sep; 122: 21-26.

                


                  Gushchina LV, Frair EC, Rohan N, Bradley AJ, Simmons TR, Chavan HD, Chou HJ, Eggers M, Waldrop MA, Wein N, Flanigan KM. Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce DMD Exon 2 Skipping. Hum Gene Ther. 2021 Sep; 32: 882-894.

                


                  Lee BH, Waldrop MA, Connolly AM, Ciafaloni E. Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy. Muscle Nerve. 2021 Aug; 64: 153-155.

                


                  Nicolau S, Waldrop MA, Connolly AM, Mendell JR. Spinal Muscular Atrophy. Semin Pediatr Neurol. 2021 Apr; 37: 100878.

                


                  Abreu NJ, Waldrop MA. Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy. Pediatr Pulmonol. 2021 Apr; 56: 710-720.

                


                  Nizon M, Laugel V, Flanigan KM, Pastore M, Waldrop MA, Rosenfeld JA, Marom R, Xiao R, Gerard A, Pichon O, Le Caignec C, Gérard M, Dieterich K, Truitt Cho M, McWalter K, Hiatt S, Thompson ML, Bézieau S, Wadley A, Wierenga KJ, Egly JM, Isidor B. Variants in MED12L, encoding a subunit of the mediator kinase module, are responsible for intellectual disability associated with transcriptional defect. Genet Med. 2019 Dec; 21: 2713-2722.

                


                  Waldrop MA, Flanigan KM. Update in Duchenne and Becker muscular dystrophy. Curr Opin Neurol. 2019 Oct; 32: 722-727.

                


                  Nizon M, Laugel V, Flanigan KM, Pastore M, Waldrop MA, Rosenfeld JA, Marom R, Xiao R, Gerard A, Pichon O, Le Caignec C, Gérard M, Dieterich K, Truitt Cho M, McWalter K, Hiatt S, Thompson ML, Bézieau S, Wadley A, Wierenga KJ, Egly JM, Isidor B. Correction: Variants in MED12L, encoding a subunit of the Mediator kinase module, are responsible for intellectual disability associated with transcriptional defect. Genet Med. 2019 Jul 3;  

                


                  Waldrop MA, Kolb SJ. Current Treatment Options in Neurology-SMA Therapeutics. Curr Treat Options Neurol. 2019 Apr 29; 21: 25.

                


                  Waldrop MA, Pastore M, Schrader R, Sites E, Bartholomew D, Tsao CY, Flanigan KM. Diagnostic Utility of Whole Exome Sequencing in the Neuromuscular Clinic. Neuropediatrics. 2019 Apr; 50: 96-102.

View More Publications

                  Flanigan KM, Vetter TA, Simmons TR, Iammarino M, Frair EC, Rinaldi F, Chicoine LG, Harris J, Cheatham JP, Cheatham SL, Boe B, Waldrop MA, Zygmunt DA, Packer D, Martin PT. A first-in-human phase I/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2. Mol Ther Methods Clin Dev. 2022 Dec 8; 27: 47-60.

                


                  Waldrop MA, Moore SA, Mathews KD, Darbro BW, Medne L, Finkel R, Connolly AM, Crawford TO, Drachman D, Wein N, Habib AA, Krzesniak-Swinarska MA, Zaidman CM, Collins JJ, Jokela M, Udd B, Day JW, Ortiz-Guerrero G, Statland J, Butterfield RJ, Dunn DM, Weiss RB, Flanigan KM. Intron Mutations and Early Transcription Termination in Duchenne and Becker muscular dystrophy. Hum Mutat. 2022 Feb 14;  

                


                  Zambon AA, Waldrop MA, Alles R, Weiss RB, Conroy S, Moore-Clingenpeel M, Previtali S, Flanigan KM, Italian DMD Network and the United Dystrophinopathy Project (UDP).. Phenotypic Spectrum of Dystrophinopathy Due to Duchenne Muscular Dystrophy Exon 2 Duplications. Neurology. 2021 Dec 22;  

                


                  Wein N, Dunn DM, Waldrop MA, Gushchina LV, Frair EC, Weiss RB, Flanigan KM. Absence of Significant Off-Target Splicing Variation with a U7snRNA Vector Targeting DMD Exon 2 Duplications. Hum Gene Ther. 2021 Nov; 32: 1346-1359.

                


                  Alfano LN, Iammarino MA, Reash NF, Powers BR, Shannon K, Connolly AM, Waldrop MA, Noritz GH, Shell R, Tsao CY, Flanigan KM, Mendell JR, Lowes LP. Validity and Reliability of the Neuromuscular Gross Motor Outcome. Pediatr Neurol. 2021 Sep; 122: 21-26.

                


                  Gushchina LV, Frair EC, Rohan N, Bradley AJ, Simmons TR, Chavan HD, Chou HJ, Eggers M, Waldrop MA, Wein N, Flanigan KM. Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce DMD Exon 2 Skipping. Hum Gene Ther. 2021 Sep; 32: 882-894.

                


                  Lee BH, Waldrop MA, Connolly AM, Ciafaloni E. Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy. Muscle Nerve. 2021 Aug; 64: 153-155.

                


                  Nicolau S, Waldrop MA, Connolly AM, Mendell JR. Spinal Muscular Atrophy. Semin Pediatr Neurol. 2021 Apr; 37: 100878.

                


                  Abreu NJ, Waldrop MA. Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy. Pediatr Pulmonol. 2021 Apr; 56: 710-720.

                


                  Nizon M, Laugel V, Flanigan KM, Pastore M, Waldrop MA, Rosenfeld JA, Marom R, Xiao R, Gerard A, Pichon O, Le Caignec C, Gérard M, Dieterich K, Truitt Cho M, McWalter K, Hiatt S, Thompson ML, Bézieau S, Wadley A, Wierenga KJ, Egly JM, Isidor B. Variants in MED12L, encoding a subunit of the mediator kinase module, are responsible for intellectual disability associated with transcriptional defect. Genet Med. 2019 Dec; 21: 2713-2722.

                


                  Waldrop MA, Flanigan KM. Update in Duchenne and Becker muscular dystrophy. Curr Opin Neurol. 2019 Oct; 32: 722-727.

                


                  Nizon M, Laugel V, Flanigan KM, Pastore M, Waldrop MA, Rosenfeld JA, Marom R, Xiao R, Gerard A, Pichon O, Le Caignec C, Gérard M, Dieterich K, Truitt Cho M, McWalter K, Hiatt S, Thompson ML, Bézieau S, Wadley A, Wierenga KJ, Egly JM, Isidor B. Correction: Variants in MED12L, encoding a subunit of the Mediator kinase module, are responsible for intellectual disability associated with transcriptional defect. Genet Med. 2019 Jul 3;  

                


                  Waldrop MA, Kolb SJ. Current Treatment Options in Neurology-SMA Therapeutics. Curr Treat Options Neurol. 2019 Apr 29; 21: 25.

                


                  Waldrop MA, Pastore M, Schrader R, Sites E, Bartholomew D, Tsao CY, Flanigan KM. Diagnostic Utility of Whole Exome Sequencing in the Neuromuscular Clinic. Neuropediatrics. 2019 Apr; 50: 96-102.

View More Publications

• Flanigan KM, Vetter TA, Simmons TR, Iammarino M, Frair EC, Rinaldi F, Chicoine LG, Harris J, Cheatham JP, Cheatham SL, Boe B, Waldrop MA, Zygmunt DA, Packer D, Martin PT. A first-in-human phase I/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2. Mol Ther Methods Clin Dev. 2022 Dec 8; 27: 47-60.
• Waldrop MA, Moore SA, Mathews KD, Darbro BW, Medne L, Finkel R, Connolly AM, Crawford TO, Drachman D, Wein N, Habib AA, Krzesniak-Swinarska MA, Zaidman CM, Collins JJ, Jokela M, Udd B, Day JW, Ortiz-Guerrero G, Statland J, Butterfield RJ, Dunn DM, Weiss RB, Flanigan KM. Intron Mutations and Early Transcription Termination in Duchenne and Becker muscular dystrophy. Hum Mutat. 2022 Feb 14;
• Zambon AA, Waldrop MA, Alles R, Weiss RB, Conroy S, Moore-Clingenpeel M, Previtali S, Flanigan KM, Italian DMD Network and the United Dystrophinopathy Project (UDP).. Phenotypic Spectrum of Dystrophinopathy Due to Duchenne Muscular Dystrophy Exon 2 Duplications. Neurology. 2021 Dec 22;
• Wein N, Dunn DM, Waldrop MA, Gushchina LV, Frair EC, Weiss RB, Flanigan KM. Absence of Significant Off-Target Splicing Variation with a U7snRNA Vector Targeting DMD Exon 2 Duplications. Hum Gene Ther. 2021 Nov; 32: 1346-1359.
• Alfano LN, Iammarino MA, Reash NF, Powers BR, Shannon K, Connolly AM, Waldrop MA, Noritz GH, Shell R, Tsao CY, Flanigan KM, Mendell JR, Lowes LP. Validity and Reliability of the Neuromuscular Gross Motor Outcome. Pediatr Neurol. 2021 Sep; 122: 21-26.
• Gushchina LV, Frair EC, Rohan N, Bradley AJ, Simmons TR, Chavan HD, Chou HJ, Eggers M, Waldrop MA, Wein N, Flanigan KM. Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce DMD Exon 2 Skipping. Hum Gene Ther. 2021 Sep; 32: 882-894.
• Lee BH, Waldrop MA, Connolly AM, Ciafaloni E. Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy. Muscle Nerve. 2021 Aug; 64: 153-155.
• Nicolau S, Waldrop MA, Connolly AM, Mendell JR. Spinal Muscular Atrophy. Semin Pediatr Neurol. 2021 Apr; 37: 100878.
• Abreu NJ, Waldrop MA. Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy. Pediatr Pulmonol. 2021 Apr; 56: 710-720.
• Nizon M, Laugel V, Flanigan KM, Pastore M, Waldrop MA, Rosenfeld JA, Marom R, Xiao R, Gerard A, Pichon O, Le Caignec C, Gérard M, Dieterich K, Truitt Cho M, McWalter K, Hiatt S, Thompson ML, Bézieau S, Wadley A, Wierenga KJ, Egly JM, Isidor B. Variants in MED12L, encoding a subunit of the mediator kinase module, are responsible for intellectual disability associated with transcriptional defect. Genet Med. 2019 Dec; 21: 2713-2722.
• Waldrop MA, Flanigan KM. Update in Duchenne and Becker muscular dystrophy. Curr Opin Neurol. 2019 Oct; 32: 722-727.
• Nizon M, Laugel V, Flanigan KM, Pastore M, Waldrop MA, Rosenfeld JA, Marom R, Xiao R, Gerard A, Pichon O, Le Caignec C, Gérard M, Dieterich K, Truitt Cho M, McWalter K, Hiatt S, Thompson ML, Bézieau S, Wadley A, Wierenga KJ, Egly JM, Isidor B. Correction: Variants in MED12L, encoding a subunit of the Mediator kinase module, are responsible for intellectual disability associated with transcriptional defect. Genet Med. 2019 Jul 3;
• Waldrop MA, Kolb SJ. Current Treatment Options in Neurology-SMA Therapeutics. Curr Treat Options Neurol. 2019 Apr 29; 21: 25.
• Waldrop MA, Pastore M, Schrader R, Sites E, Bartholomew D, Tsao CY, Flanigan KM. Diagnostic Utility of Whole Exome Sequencing in the Neuromuscular Clinic. Neuropediatrics. 2019 Apr; 50: 96-102.

Education

Date of Appointment at Nationwide Children’s Hospital: 04/01/2018

Board Certifications

Child Neurology Neurology Neuromuscular Medicine

Fellowship

Nationwide Children’s Hospital

Date Completed: 03/31/2018

Fellowship

Ohio State University Wexner Medical Center

Date Completed: 06/30/2017

Residency

University of California Irvine Medical Center

Date Completed: 06/30/2016

Residency

University of California Irvine Medical Center

Date Completed: 06/30/2013

Medical School

Albany Medical College

Date Completed: 05/26/2011

Education

Date of Appointment at Nationwide Children’s Hospital: 04/01/2018

Board Certifications

Child Neurology Neurology Neuromuscular Medicine

Fellowship

Nationwide Children’s Hospital

Date Completed: 03/31/2018

Fellowship

Ohio State University Wexner Medical Center

Date Completed: 06/30/2017

Residency

University of California Irvine Medical Center

Date Completed: 06/30/2016

Residency

University of California Irvine Medical Center

Date Completed: 06/30/2013

Medical School

Albany Medical College

Date Completed: 05/26/2011

Education

Date of Appointment at Nationwide Children’s Hospital: 04/01/2018

Board Certifications

Child Neurology Neurology Neuromuscular Medicine

Fellowship

Nationwide Children’s Hospital

Date Completed: 03/31/2018

Fellowship

Ohio State University Wexner Medical Center

Date Completed: 06/30/2017

Residency

University of California Irvine Medical Center

Date Completed: 06/30/2016

Residency

University of California Irvine Medical Center

Date Completed: 06/30/2013

Medical School

Albany Medical College

Date Completed: 05/26/2011

Date of Appointment at Nationwide Children’s Hospital: 04/01/2018

Board Certifications

Child Neurology Neurology Neuromuscular Medicine

Fellowship

Nationwide Children’s Hospital

Date Completed: 03/31/2018

Fellowship

Ohio State University Wexner Medical Center

Date Completed: 06/30/2017

Residency

University of California Irvine Medical Center

Date Completed: 06/30/2016

Residency

University of California Irvine Medical Center

Date Completed: 06/30/2013

Medical School

Albany Medical College

Date Completed: 05/26/2011

Date of Appointment at Nationwide Children’s Hospital: 04/01/2018

Board Certifications

Child Neurology Neurology Neuromuscular Medicine

Fellowship

Nationwide Children’s Hospital

Date Completed: 03/31/2018

Fellowship

Ohio State University Wexner Medical Center

Date Completed: 06/30/2017

Residency

University of California Irvine Medical Center

Date Completed: 06/30/2016

Residency

University of California Irvine Medical Center

Date Completed: 06/30/2013

Medical School

Albany Medical College

Date Completed: 05/26/2011

• Child Neurology
• Neurology
• Neuromuscular Medicine

Contact Information

Pediatrics

Call us at: (614) 722-2203

Fax us at: (614) 355-5247

                    Neurology700 Children's DrColumbus, OH 43205 (map)

Contact Information

Pediatrics

Call us at: (614) 722-2203

Fax us at: (614) 355-5247

                    Neurology700 Children's DrColumbus, OH 43205 (map)

Contact Information

Pediatrics

Call us at: (614) 722-2203

Fax us at: (614) 355-5247

                    Neurology700 Children's DrColumbus, OH 43205 (map)

Pediatrics

Call us at: (614) 722-2203

Fax us at: (614) 355-5247

                    Neurology700 Children's DrColumbus, OH 43205 (map)

Call us at: (614) 722-2203

Fax us at: (614) 355-5247

                    Neurology700 Children's DrColumbus, OH 43205 (map)

Call us at: (614) 722-2203

Fax us at: (614) 355-5247

                    Neurology700 Children's DrColumbus, OH 43205 (map)

• Call us at:
• (614) 722-2203
• Fax us at:
• (614) 355-5247
• Neurology700 Children’s DrColumbus, OH 43205 (map)